[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dengue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dengue":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,45,71,101,127,151,184,209,236,260,291,387,413,442,469,493,520,545,565,596],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643532","gut-leakage-in-dengue-100643532",false,"NCT07602920","Gut Leakage' in Dengue","Gut Leakage and Sonographic Abdominal Changes in Hospitalized Dengue Patients: an Observational Study","GLiD","Inclusion Criteria:\n\nDengue participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Diagnosed as a case of Dengue on the basis of clinical features and positive NS1 antigen and\u002For IgM dengue antibody\n* Hospitalized in medicine or dengue ward in Chittagong Medical College Hospital.\n* Enrolled within 24 hours of hospitalization.\n\nHealthy participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Clinically healthy with no acute or chronic illness\n* Attendant of a dengue patient (not a patient)\n\nExclusion Criteria:\n\nDengue participants\n\n* Unable to provide consent or participate in follow-up procedures\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n\nHealthy participants\n\n* Unable to provide consent\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n* History of current or recent dengue or other arbo viral infection",true,"ALL","18 Years",{"count":21,"type":22},190,"ESTIMATED","OBSERVATIONAL","Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the development of medical counter measures because of the high risk of it causing a Public Health Emergency of Intenational Concern (PHEIC). Warning signs for severe dengue, associated with mortality, include gastrointestinal features including abdominal pain, vomiting, and diarrhoea. Multiple alterations may occur in in the gastrointestinal tract that could lead to damaging of the gastrointestinal wall and gut leakage, the translocation of gut metabolites into the bloodstream. Study team hypothesize that gut leakage initiates inflammatory processes underlying the further development of severe dengue, including features associated with plasma leakage.\n\nThis study aims to investigate intestinal barrier dysfunction (gut leakage) in dengue infection by detecting the translocation of gut-derived bacteria and their products (Lipopolysaccharides, LPS binding protein, sCD14, I-Fatty Acid Binding Protein) into the bloodstream. Study team will recruit hospitalized adult dengue patients (18 years and older) presenting with warning signs or severe disease in a tertiary care public hospital at Chattogram, Bangladesh. Circulating biomarkers indicative of gut permeability and microbial translocation will be measured to assess their presence and association with disease severity.\n\nAbdominal ultrasonography will be performed to characterize gastrointestinal alterations and determine their correlation with biochemical markers of gut leakage and clinical severity. In addition, study team will analyze the gut bacteriome from stool\u002F rectal swab of these patients to explore whether dengue infection induces compositional changes in intestinal microbiota and whether such alterations are linked to gut leakage or disease progression.",[26,27,28,29,30,31],"Dengue","Dengue Hemorrhagic Fever","Intestinal Disease","Ascites","Dengue With Warning Signs","Gut Microbiome","NOT_YET_RECRUITING","2026-06-08",{"date":35,"type":36},"2026-06-10","ACTUAL",{"date":38,"type":22},"2026-07-01",{"date":40,"type":22},"2028-01-31",{"name":42,"class":43},"University of Oxford","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100594198","phase-2-emetine-for-viral-outbreaks-aka-evolve-antiviral-initiative-100594198","NCT07016321","Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)","Emetine for Viral Outbreaks: A Phase 2\u002F3 Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Emetine for Dengue Fever (a.k.a. EVOLVE Antiviral Initiative)","Inclusion Criteria:\n\n1. Age 18 to 65 years\n2. Admitted to the hospital\n3. Laboratory-confirmed infection with dengue virus within the last 5 days and preferably within the last 3 days. Testing for dengue virus using positive Nonstructural protein 1(NS1) strip assay or reverse-transcriptase polymerase chain reaction (RT-PCR)\n4. Having two or more clinical symptoms (fever, headache, retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestations, or leucopenia, gastrointestinal symptoms) with the onset of fever within 72 hours of presentation, and\n5. Able to provide voluntary informed consent and comply with all study procedures and visits.\n\nExclusion Criteria:\n\n1. Age ≥65 years\n2. Pregnant or breastfeeding\n3. Current or recent use of the study drug\n4. Known allergy to study drug\n5. Current or planned participation in another pharmacological interventional trial in the next 10 days\n6. Participants with known past history of dengue infection\n7. Participants on aspirin, anticoagulants, or with other conditions that might increase the risk of bleeding\n8. Participants on immunosuppressive agents, including long-term steroids\n9. Severe dengue as defined by the WHO 2009 revised case classification.\n10. Individuals with long-term immunosuppressive agents such as anti-cancer chemotherapy or radiation therapy within the past 6 months, or those on systemic corticosteroid therapy\n11. History of prior vaccination against dengue fever within one year.\n12. Patients who have recently used ayurvedic or herbal medications for dengue or any other conditions in the last 7 days (eg, Papaya leaf extract)","65 Years",{"count":54,"type":22},600,"INTERVENTIONAL",[57,58],"PHASE2","PHASE3","The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are:\n\n1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)?\n2. What are the safety outcomes of emetine, including serious adverse events and toxicities?\n\nParticipants will be asked to:\n\n1. Take either 6mg emetine, 12mg emetine, or a placebo pill for 7 consecutive days as part of the treatment regimen.\n2. Have blood samples taken for at least 5 days to monitor viral load, inflammatory markers, and safety parameters.\n3. Be monitored by healthcare staff for daily vital signs and symptoms for clinical assessments for 28 days.",[26],"2026-06-02",{"date":63,"type":36},"2026-06-03",{"date":65,"type":22},"2026-06-25",{"date":67,"type":22},"2029-05-03",{"name":69,"class":43},"Johns Hopkins University",2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":55,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100640150","effects-of-a-rehabilitation-protocol-on-muscle-strength-muscle-fatigue-and-postural-control-in-post-dengue-and-chikungunya-patients-100640150","NCT07600879","Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients","Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients: Non-Randomized Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Individuals of both sexes\n* Residents of the 1st, 4th, or 11th Health Regions of the state of Pará\n* Confirmed diagnosis of Dengue (DENV) and\u002For Chikungunya (CHIKV) infection by serological testing (ELISA or IgG\u002FIgM)\n* Diagnosis confirmed within the last 5 years\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Hemodynamic instability\n* Musculoskeletal instability, including fractures or acute muscle injuries\n* Cognitive deficits impairing the understanding of commands or study procedures\n* History of balance disorders prior to Dengue or Chikungunya infection\n* Obesity\n* Blindness or low vision\n* Hearing impairment",{"count":79,"type":22},54,[81],"NA","Introduction: Dengue and Chikungunya arboviral diseases are considered major public health challenges in tropical regions due to high infection rates and the occurrence of musculoskeletal sequelae that impair strength, balance, and functionality. After the acute phase, symptoms such as fatigue, joint pain, muscle weakness, and postural instability are common, reducing quality of life and hindering social and occupational reintegration.Objective: To analyze the effects of a rehabilitation protocol on muscle fatigue, muscle strength, and postural control in post-Dengue and Chikungunya patients.Methods: This is a non-randomized clinical trial conducted at the Integrated Laboratory for Research and Care in Infectious and Sequelae Diseases (LabDIS\u002FUEPA). Individuals of both sexes, aged over 18 years, with a confirmed diagnosis of Dengue and\u002For Chikungunya within the last five years will be included. Data collection will include a clinical interview, surface electromyography of the flexor carpi radialis, tibialis anterior, lateral and medial gastrocnemius muscles, hydraulic and electronic dynamometry, manovacuometry, and baropodometry. The rehabilitation protocol will consist of twenty supervised sessions of aerobic, anaerobic, and respiratory exercises.Expected Results: Improvements in muscle strength, muscle fatigue, and postural control are expected following the intervention.Conclusion: The findings may support physiotherapeutic strategies aimed at improving strength, fatigue, and balance, expanding knowledge on the neuromuscular and respiratory consequences of arboviral diseases, and contributing to the development of evidence-based rehabilitation protocols, with potential positive impacts on healthcare delivery and public health policies.",[26,84],"Chikungunya",[86,87,88,89,90,91,92],"dengue","Chikungunya Virus","Muscle Strength","Electromyography","Rehabilitation","Posture","Muscle Fatigue","2026-05-20",{"date":95,"type":36},"2026-05-26",{"date":38,"type":22},{"date":98,"type":22},"2027-07-30",{"name":100,"class":43},"Universidade do Estado do Pará",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":55,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":70},"100639752","phase-2-a-study-of-cp-cov03-compared-with-placebo-in-participants-with-dengue-part-1-and-dengue-like-illness-part-2-100639752","NCT07576868","A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)","A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy of CP-COV03 in Dengue Patients (Part 1) \u002F Dengue and Dengue-like Illness Patients (Part 2)","Inclusion Criteria:\n\n* Patients who are 18 years or over of age at time of screening.\n* Patients who have at least two symptoms with a score of 2 or higher within 72 h from fever onset.\n* Patients who are diagnosed with dengue by NS1 positive (Phase 2- Part 1 only). And patients who are classified as dengue, zika, influenza, COVID-19 and others (Phase 3- Part 2 only)\n\nExclusion Criteria:\n\n* Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or clinical laboratory results)\n* Patients who have previously received dengue vaccine\n* Patients who have chronic medical conditions such as uncontrolled diabetes mellitus, severe asthma requiring oral steroids or admission to the hospital in the previous 6 months for cardiac disease",{"count":109,"type":22},210,[57,58],"This is a randomized, double-blind, placebo-controlled Phase 2\u002F3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.",[26],[86,114,115],"dengue treatment","dengue antiviral","RECRUITING","2026-05-04",{"date":119,"type":36},"2026-05-08",{"date":121,"type":36},"2026-04-09",{"date":123,"type":22},"2027-05",{"name":125,"class":126},"Hyundai Bioscience Co., Ltd.","INDUSTRY",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":18,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":55,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":70},"100558494","phase-2-adaptive-dengue-antiviral-platform-trial-100558494","NCT06551844","Adaptive Dengue Antiviral Platform Trial","Adaptive Dengue Antiviral Platform Trial (ADAPT): a Phase 2 Randomized, Adaptive, Open Label Trial for Antiviral Screening in Patients With Early Symptomatic Dengue","ADAPT","Inclusion Criteria:\n\n* Female or male patients with a clinical diagnosis of dengue virus infection and less than 48 hours of fever\n* Positive NS1 rapid diagnostic test\n* \\>= 10 years or ≥ 18 years of age (depending on license of therapeutic being evaluated)\n* Patient is able to give written informed consent or assent for full participation in the study.\n* Agreement to stay in hospital for duration of the intervention (most will be 5 days) and follow-up visits at day 30 and 60 post enrolment.\n\nExclusion Criteria:\n\n* Meets criteria for severe dengue at baseline (severe plasma leakage leading to dengue shock syndrome, fluid accumulation with respiratory distress, severe bleeding, severe organ involvement - AST\u002FALT\\>1000 U\u002FL, impaired consciousness, multiple organ dysfunction)\n* Pregnancy (either clinically confirmed or by urine dipstick for human chorionic gonadotrophin hormone)\n* Breastfeeding women\n* Localising features suggesting an alternative\u002Fadditional diagnosis, e.g. pneumonia, sepsis\n* Renal failure (baseline eGFR \\\u003C 30ml\u002Fmin)\n* History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neuropsychiatric, autoimmune, dermatologic or immunosuppressive disorders\n* History of allergic disease, allergic reactions or known hypersensitivity to any component of the study product (Mild non-medication allergies allowed)\n* Any condition that, in the opinion of the investigator, would complicate or compromise the study or well-being of the participant\n* Participation or planned participation in a study involving the administration of an investigational compound within the past one month.","10 Years",{"count":137,"type":22},500,[57],"This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection\n\n* Primary objectives:\n\n  * To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection\n  * To assess the safety and tolerability of the experimental drug(s) in dengue patients\n* Secondary objective:\n\n  * To assess the effect of the experimental drug(s) in dengue patients on physiological, clinical and virological parameters",[26,141],"Antiviral Drugs","2026-04-24",{"date":144,"type":36},"2026-04-30",{"date":146,"type":36},"2026-04-20",{"date":148,"type":22},"2030-12-31",{"name":150,"class":43},"Oxford University Clinical Research Unit, Vietnam",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":18,"minAge":159,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":55,"phases":162,"briefSummary":163,"conditions":164,"keywords":172,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},"100634728","phase-3-therapeutics-for-moderate-and-severe-dengue-100634728","NCT07543458","Therapeutics for Moderate and Severe Dengue","A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)","DEN-HOST","Inclusion Criteria:\n\n* Age ≥5 years\n* Decision to hospitalise\n* Clinical diagnosis of dengue\n* Participants must also have at least one of the following:\n\n  1. Severe abdominal pain or tenderness\n  2. Vomiting more than 3 times in the past 24 hours\n  3. Pleural effusion or ascites on clinical or radiological examination\n  4. Absolute haematocrit \\>50%\n  5. 15% increase in haematocrit compared with a baseline sample (defined as the first sample taken during the current illness)\n  6. Absolute platelet count \\\u003C50 × 10⁹\u002FL\n  7. Absolute platelet count \\\u003C100 × 10⁹\u002FL AND a drop \\>50 × 10⁹\u002FL in the past 32 hours\n  8. ALT or AST \\>400 IU\u002FL\n  9. Pulse pressure \\\u003C20mmHg or hypotension for age AND at least one of: peripheral capillary refill time \\>2 seconds; urine output 0.5ml\u002Fkg\u002Fhr; cold\u002Fclammy peripheries; agitation or altered mental state\n  10. Bleeding leading to hypotension for age or requiring blood transfusion or medical intervention (e.g. surgery, endoscopy, or vasoactive drugs)\n  11. Symptomatic bleeding into a critical site (intracranial, intraspinal, intraocular with visual impairment, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome)\n  12. Requirement for organ support, including vasopressors or inotropes, assisted ventilation, dialysis or haemofiltration, or coma (unresponsive to pain without sedation) or requirement for intravenous antiseizure medications\n\nExclusion Criteria:\n\n* Patients on ≥ day 10 of illness or who are clinically improving in the opinion of the managing doctor (the 'recovery phase') will be excluded from recruitment. Other exclusion criteria are specific to individual treatment comparisons, and do not preclude randomisation to other arms of the study.\n* A participant may not enter a specific treatment comparison if that treatment is considered to be indicated or contraindicated by the responsible clinician.","5 Years",{"count":161,"type":22},8800,[58],"The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.",[26,165,166,167,168,169,170,171],"Severe Dengue","Mosquito-Borne Diseases","Vector Borne Diseases","Arbovirus Infections","Flavivirus Infections","RNA Virus Infections","Hemorrhagic Fever",[114,173,174],"host-directed therapy","host-targeted therapeutics","2026-04-15",{"date":177,"type":36},"2026-04-21",{"date":179,"type":22},"2026-10-01",{"date":181,"type":22},"2031-07-31",{"name":150,"class":43},18,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":55,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":208},"100516595","phase-2-a-study-to-assess-the-efficacy-safety-and-pharmacokinetics-of-eyu688-in-patients-with-dengue-fever-100516595","NCT06006559","A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever","A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever","Inclusion Criteria:\n\n* Male or female, 18 - 60 years old (inclusive).\n* History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection:\n* Nausea or vomiting.\n* Presence of rash, aches or pains including headache, muscle or joint pain.\n* Onset of fever ≤ 48 hours prior to treatment start.\n* Positive test on dengue fever.\n\nExclusion Criteria:\n\n* Participants with any of abnormalities of clinical laboratory parameters.\n* Usage of any anticoagulant drugs.\n* Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.\n* Pregnant or nursing (lactating) women.\n* Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.\n* Participants with any of the following abnormalities of clinical laboratory parameters at screening:\n\n  * Hemoglobin \\\u003C12.0 g\u002FdL in males; \\\u003C11.0 g\u002FdL in females\n  * Hematocrit \\>52 % in males; \\>46 % in females\n  * Absolute neutrophil count \\\u003C1500\u002FμL\n  * Platelet count \\\u003C80,000\u002Fmm3\n  * Creatinine \\>165 μmol\u002FL in males; \\>130 μmol\u002FL in females\n  * Serum creatine kinase \\> 600 U\u002FL\n  * ALT, AST levels more than 1.5X upper limit of normal (ULN)\n  * Total bilirubin \\>24 μmol\u002FL\n* Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening.\n* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.\n* History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening:\n\n  * QTcF \\> 450 msec (males)\n  * QTcF \\> 460 msec (females)\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","60 Years",{"count":193,"type":22},108,[57],"The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.",[26],[26,198],"EYU688","2026-03-23",{"date":201,"type":36},"2026-03-24",{"date":203,"type":36},"2024-02-20",{"date":205,"type":22},"2027-01-15",{"name":207,"class":126},"Novartis Pharmaceuticals",23,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":55,"phases":219,"briefSummary":220,"conditions":221,"keywords":222,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":235},"100590926","phase-3-trial-to-evaluate-the-immunogenicity-and-safety-of-the-co-administration-of-live-attenuated-dengue-and-chikungunya-vaccines-compared-to-separate-administration-in-adults-aged-18-to-59-years-100590926","NCT06973772","Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.","Phase 3b, Multicenter, Randomized, Controlled, Double-Blind Clinical Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines in Adults Aged 18 to 59 Years.","Inclusion Criteria:\n\n1. Male or female adults aged 18 to 59 years at the time of vaccination.\n2. Signed informed consent by the participant or their legal representatives.\n3. Ability to understand, based on the investigator's assessment, and agree to comply with all study procedures, including blood collection.\n\nExclusion Criteria:\n\n1. Participation in another clinical trial within 28 days prior to screening or planned participation in another clinical study during the trial period.\n2. Pre-existing unstable health condition. An unstable health condition is defined as a disease requiring a change in treatment or hospitalization due to disease worsening within 90 days prior to screening.\n3. Vaccination within 14 days prior to screening with any inactivated vaccine or within 28 days prior to screening with any live attenuated vaccine, or planned vaccination with any vaccine up to 28 days after study vaccination.\n4. Known hypersensitivity to any component of the vaccines.\n5. Thrombocytopenia or bleeding disorders that contraindicate intramuscular vaccination or venipuncture for blood collection.\n6. Receipt of immunoglobulins, blood, or blood products within 180 days prior to screening.\n7. Altered immunocompetence (immunosuppression, immunodeficiency, or immunocompromise) primary or secondary due to: Clinical conditions (including but not limited to renal failure, liver failure with cirrhosis, heart failure class III or IV according to the New York Heart Association, HIV infection, and asplenia).\n8. Use of systemic corticosteroids (oral, intravenous, or intramuscular) at a dose equivalent to ≥20 mg\u002Fday of prednisone for more than 14 days or a cumulative dose greater than 280 mg within the last 90 days prior to screening. Topical, inhaled, and intranasal corticosteroids are allowed. Intermittent use (a single dose within the last 30 days prior to screening) of intra-articular corticosteroids is also allowed.\n9. Receipt of antineoplastic agents, immunosuppressants, immunomodulators, or radiotherapy within the last 180 days prior to screening.\n10. Malignancy at the time of screening or a history of malignancy with \\\u003C5 years of disease-free status at screening (except for basal cell carcinoma of the skin and localized prostate cancer under active surveillance).\n11. Abuse of alcohol and illicit drugs within the past 12 months before screening that may compromise study compliance, at the investigator's discretion.\n12. Being part of the study team, having a first-degree relative (parents, children, in-laws, stepchildren, sons-in-law, or daughters-in-law) or living in the same household as a study team member.\n13. Any other clinical condition that, in the investigator's opinion, may interfere with the study results or pose an additional risk to the participant due to study inclusion.\n14. Prior exposure to dengue and chikungunya viruses, i.e., non-reactive IgM and IgG as screened by specific ELISA for both viruses. In case of doubt or indeterminate ELISA results, at least two consecutive samples will be collected. If doubt persists after two test collections, the participant will be excluded.\n15. For female participants of childbearing potential: Pregnancy (confirmed by a positive β-hCG test), breastfeeding, or intention to engage in sexual activity with reproductive potential without using a contraceptive method for 90 days following vaccination.\n16. Previous receipt of any dengue or chikungunya vaccine.","59 Years",{"count":218,"type":22},900,[58],"This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the adult population aged 18 to 59 years without prior exposure to either arbovirus.",[26,84],[86,223,224],"chikungunya","coadministration regimen","2026-03-05",{"date":227,"type":36},"2026-03-06",{"date":229,"type":22},"2026-03-31",{"date":231,"type":22},"2026-10",{"name":233,"class":234},"Butantan Institute","OTHER_GOV",7,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":17,"sex":18,"minAge":244,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":55,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":259},"100584638","phase-3-butantan-dv-vaccine-in-elderly-populations-den-04-ib-100584638","NCT06891950","Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)","Phase 3B, Double-blind, Randomized Study to Evaluate the Safety and Non-inferiority of the Humoral Immune Response of the Butantan Dengue Vaccine in Participants Aged 60 to 79 Years Compared to Participants Aged 40 to 59 Years","DEN-04-IB","Inclusion Criteria:\n\n* a. Healthy participants aged between 40 and 79 years at the time of study entry, with or without a history of exposure to dengue fever;\n\n  b. Agree to periodic contact by telephone, electronic means, and home visits and to the research center;\n\n  c. Participants with reproductive potential must be using some effective contraceptive method at screening and continue using it for up to 90 days after the intervention; except in cases where the volunteer declares that she is not at risk of becoming pregnant, either by not engaging in sexual activities or by engaging in them in a non-reproductive manner, up to 90 days after vaccination;\n\n  d. Demonstrate intent to participate in the study, documented by the participant's signature of the informed consent form, as well as the study procedures, including completing the Participant Diaries, blood collection, and being available for scheduled study visits and contacts.\n\nExclusion Criteria:\n\n* a. For female participants with reproductive potential: pregnancy (confirmed by positive β-hCG test), breastfeeding or manifest intention to have sexual practices with reproductive potential without using a contraceptive method in the 90 days following vaccination;\n\n  b. Planned donation of blood, semen or eggs in the 90 days following vaccination;\n\n  c. Evidence of active uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease according to anamnesis or physical examination, at the discretion of the investigator;\n\n  d. Diseases that compromise the immune system, including: decompensated diabetes mellitus, active neoplasms or history of neoplasms in the last five years (except basal cell carcinoma), congenital or acquired immunodeficiencies (including HIV\u002FAIDS), solid organ transplants (heart, liver, pancreas, lung, kidney) or uncontrolled autoimmune diseases according to anamnesis or physical examination, as well as a history of liver failure, heart failure or terminal chronic kidney disease or dialysis;\n\n  e. Behavioral, cognitive, or psychiatric illness that, in the opinion of the principal investigator or his\u002Fher medical representative, affects the potential participant's ability to understand and comply with the requirements of the study protocol;\n\n  f. Any abuse of alcohol or drugs in the last 12 months prior to enrollment in the study that has caused medical, professional, or family problems, as indicated by the clinical history;\n\n  g. History of severe allergic reaction or anaphylaxis to the vaccine or components of the study vaccine;\n\n  h. History of asplenia;\n\n  i. Participation in another clinical trial with administration of an investigational product during the six months prior to enrollment in the study or scheduled participation in another clinical trial in the 12 months following enrollment;\n\n  j. Previous participation in a dengue vaccine evaluation study or previous exposure to dengue vaccine;\n\n  k. Use of immunosuppressive therapies six months prior to enrollment in the study or their scheduled use in the 12 months following enrollment. The following immunosuppressive therapies will be considered: antineoplastic chemotherapy, radiotherapy, immunosuppressants to induce tolerance to transplants, monoclonal antibody therapy for the treatment of rheumatological diseases, among others;\n\n  l.Having received an immunosuppressive dose of corticosteroid in the last three months prior to inclusion in the study or administration of an immunosuppressive dose of corticosteroid for the 12 months following inclusion in the study. The dose of corticosteroid considered immunosuppressive is the equivalent of prednisone at a dose of 20 mg\u002Fday, for adults, for 14 days (cumulative dose equivalent to at least 280 mg of prednisone). Continuous use of topical or nasal corticosteroid is not considered immunosuppressive;\n\n  m. Having received blood products (transfusions or immunoglobulins) in the last three months prior to inclusion in the study, or scheduled administration of blood products or immunoglobulin in the 12 months following inclusion in the study;\n\n  n. Fever, suspected or measured, in the 72 hours prior to vaccination or axillary temperature ≥ 37.8°C on the day of vaccination (inclusion may be postponed until the potential participant has been fever-free for 72 hours);\n\n  o. Having received a live attenuated virus vaccine in the last 28 days or an inactivated vaccine in the last 14 days prior to inclusion in the study, or having been immunized within 12 months of inclusion in the study;\n\n  p. Any other condition that, in the opinion of the principal investigator or his\u002Fher medical representative, may jeopardize the safety or rights of a potential participant or that prevents him\u002Fher from complying with this protocol.","40 Years","79 Years",{"count":247,"type":22},997,[58],"This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue vaccine (Dengue 1,2,3,4 (attenuated)) in participants aged 60 -79 years (elderly) compared to participants aged 40 to 59 years (adults), with or without previous dengue and healthy based on clinical examination.",[26],[252,253],"dengue vaccine","elderly population",{"date":227,"type":36},{"date":256,"type":36},"2026-03-03",{"date":231,"type":22},{"name":233,"class":234},5,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":17,"sex":18,"minAge":267,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":55,"phases":270,"briefSummary":271,"conditions":272,"keywords":273,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":44},"100624657","a-controlled-human-infection-model-of-dengue-100624657","NCT07412483","A Controlled Human Infection Model of Dengue","DEN-CHIM-01","Inclusion Criteria:\n\n1. An informed consent form (ICF) has been signed and dated by the participant, an investigator, and a witness\n2. Adult, aged between 21 and 45 years, inclusive (at the time of consent)\n3. No known history of prior dengue, zika or other Orthoflavivirus infection\n4. No history of prior dengue, yellow fever, Japanese encephalitis virus, or other Orthoflavivirus vaccination\n5. Sero-suitable based on the pre-screening serology result\n6. a Female participants must be willing and able to use contraception from 2 weeks before the scheduled date of viral challenge until 1 month after receipt of the final dose of study virus. Negative urine pregnancy tests will be required at screening, and on admission to the quarantine unit a negative serum beta human chorionic gonadotropin (β-hCG) is required prior to inoculation.\n\n6b Male participants who are willing to use one of the contraception methods described in the study protocol, from the date of viral challenge, for 1 month. In addition to the contraceptive requirements above, male participants must agree not to donate sperm following discharge from quarantine until 1 month after the date of viral challenge.\n\n7 In good health with no history of clinically significant medical conditions (as described in Exclusion criteria) that would interfere with subject safety, as defined by medical history, physical examination and routine laboratory tests, ECG, and Chest X-Ray and determined by the Investigator at an admission evaluation.\n\n8 Willing and able to commit to participation in the study.\n\nExclusion Criteria:\n\n1. History or evidence of any clinically significant or currently active neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease.\n2. History of active depression and\u002For anxiety with associated severe psychiatric comorbidities, for example psychosis.\n3. Behavioural, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the requirements of the study protocol.\n4. Significant history or presence of drug or alcohol misuse\n5. History of anaphylaxis and\u002For a history of severe allergic reaction or significant intolerance to any food or drug, as assessed by the PI.\n6. Family history of 1st degree relative aged 50 years or less with sudden cardiac or unexplained death\n7. A total body weight of ≤ 45kg and a Body Mass Index (BMI) ≤18 kg\u002Fm2 and ≥30 kg\u002Fm2.\n8. Venous access deemed inadequate for the phlebotomy demands of the study.\n9. Any clinically significant abnormal finding on screening biochemistry, haematology and microbiology blood tests or urinalysis apart from minor deviations which are clinically acceptable and approved by the investigator.\n\nAny of the following:\n\n* Elevated HbA1C\n* Positive HIV, active\u002Fchronic hepatitis B or hepatitis C test. 10 Twelve-lead ECG recording with clinically relevant abnormalities as judged by the study investigator.\n\n  11 Receipt of a live vaccine within 60 days prior to the planned date of viral challenge, a non-live vaccine within 30 days prior to the planned date of viral challenge or intention to receive any vaccination(s) before the day 28 follow-up visit.\n\n  12 Previous receipt of a flavivirus vaccine (licensed or experimental). 13 Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 3 months prior to the planned date of viral challenge or planned during the 3 months after the final visit.\n\n  14 Medications:\n  1. Receipt of any investigational drug within 3 months prior to the planned date of viral challenge\n  2. Receipt of systemic (intravenous and\u002For oral) glucocorticoids or systemic antiviral drugs within 6 months prior to the planned date of viral challenge.\n  3. Over the counter medications (e.g., paracetamol or ibuprofen) where the dose taken over the preceding 7 days prior to the planned date of viral challenge had exceeded the maximum permissible 24-hour dose (e.g., \\>4g per day of paracetamol over the preceding week).\n  4. Participants who have received any systemic chemotherapy agent, immunoglobulins, or other cytotoxic or immunosuppressive drugs at any time.\n\n  15 Participant is mentally or legally incapacitated in the opinion of the Investigator.\n\n  16 Females who:\n  1. Are breastfeeding within 6 months of study commencement, or\n  2. Had been pregnant within 6 months prior to the study, or\n  3. Had a positive pregnancy test at any point during screening or prior to inoculation with challenge virus 17 Anyone who is first degree related to anyone who is a delegated member of the research team.\n\n  18 Any other reason that the Investigator considered made the participant unsuitable to participate.\n\n  19 Presence of symptoms and\u002For fever (defined as participant presenting with a temperature reading of \\>37.9ºC) suggesting an infection at pre-challenge on Day 0.","21 Years","45 Years",{"count":259,"type":22},[81],"This study aims to conduct a safe human infection challenge using an attenuated serotype DEN3 dengue virus in adult volunteers. The clinical, viral and immune response characteristics of the model will be analysed to understand the pathophysiology of dengue fever. This data will be used to inform future studies, including a planned follow up study (DEN-CHIM-02) which will investigate the efficacy of an investigational dengue vaccine at protecting against DEN3 infection.\n\nStudy conditions that result in a safe, reproducible infection in ≥80% of research participants (attack rate) with the DEN3 challenge agent have been identified during studies conducted by our collaborators in the US. This includes the inoculum dose, safety monitoring, and necessary participant pre-screening to exclude prior Orthoflavivrus infection or vaccinations.\n\nStudy objectives are to:\n\n1. Establish in seronegative volunteers in Singapore a safe DENV controlled human infection (CHI) model, with an infection rate of ≥80%, suitable for future studies of interventions.\n2. Characterise the clinical, haematological and virological response following controlled inoculation of the attenuated DEN3 challenge agent.\n3. Conduct deep immunophenotyping to understand the cellular, humoral and innate immune response to dengue infection.\n4. Explore the longitudinal immune response in the 3 years after challenge, including following subsequent dengue vaccination.",[26],[274,275,276,277,278,279,280,281],"Human challenge study","controlled human infection model","dengue virus serotype 3","rDEN3delta30","dengue infection","dengue viremia","haematological response to dengue infection","neutralising antibodies to DEN-3","2026-02-11",{"date":284,"type":36},"2026-02-17",{"date":286,"type":22},"2026-03",{"date":288,"type":22},"2029-04",{"name":290,"class":43},"Tan Tock Seng Hospital",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":17,"sex":18,"minAge":298,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":302,"conditions":303,"keywords":360,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":44},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","2 Years","75 Years",{"count":301,"type":22},10000,"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[26,84,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359],"Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","2026-01-14",{"date":380,"type":36},"2026-01-22",{"date":382,"type":36},"2025-12-18",{"date":384,"type":22},"2027-09-30",{"name":386,"class":43},"Institut Pasteur du Cambodge",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":17,"sex":18,"minAge":394,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":4},"100608563","dengue---sample-collection-study-pakistan-100608563","NCT07203183","Dengue - Sample Collection Study Pakistan","A Prospective Study for the Collection of Whole Blood Samples to Support the Development and Validation of In Vitro Diagnostic Tests for Dengue","Inclusion Criteria:\n\n* Age ≥12-years-old\n* Individuals suspected or confirmed for active dengue, with dengue-consistent symptoms onset up to and including 10 days before enrolment in this trial.\n\nExclusion Criteria:\n\n* Subject has been vaccinated for dengue.\n* Subject participates in an investigative drug, vaccine or medical device clinical study\n* Participant is deemed unfit for the study by the Investigator\n* Participant is unwilling or unable to provide informed consent","12 Years",{"count":396,"type":22},200,"The objective of this study is to collect well-characterized serum and plasma specimens from confirmed dengue positive and dengue negative subjects to support dengue diagnostic products development.",[26],[86,400,401,402,403],"sample collection","serum","plasma","blood","2025-09-24",{"date":406,"type":36},"2025-10-02",{"date":408,"type":22},"2025-10-01",{"date":410,"type":22},"2026-04-01",{"name":412,"class":126},"Abbott Rapid Dx",{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":18,"minAge":159,"maxAge":4,"enrollmentInfo":421,"targetDuration":423,"studyType":23,"phases":4,"briefSummary":424,"conditions":425,"keywords":428,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":44},"100593526","risk-factors-for-hospitalization-and-transfusion-criteria-in-patients-with-dengue-virus-infection-100593526","NCT07007585","Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection","Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection: A Prospective Observational Study","DENGUE-FACT","Inclusion Criteria:\n\n* Patients aged ≥5 years\n* Laboratory-confirmed dengue infection (NS1, IgM, or PCR)\n* First contact at emergency or outpatient services\n* Informed consent signed by the patient or legal guardian\n\nExclusion Criteria:\n\n* Co-infection with other arboviruses or COVID-19\n* Pre-existing hematologic or oncologic disease\n* Refusal to sign informed consent",{"count":422,"type":22},100,"1 Month","This 3-year prospective observational study aims to identify clinical and laboratory risk factors associated with hospitalization in patients with confirmed dengue virus infection. It also seeks to analyze real-world transfusion practices and their outcomes. The study will be conducted in a second-level hospital in northern Mexico and will follow patients from emergency department entry to clinical resolution or hospital discharge.",[26,426,427],"Dengue Fever","Dengue Fever With Warning Signs",[26,429,430,171,431,432],"Hospitalization","Transfusion","Thrombocytopenia","Mexico","2025-09-13",{"date":435,"type":36},"2025-09-16",{"date":437,"type":36},"2025-08-01",{"date":439,"type":22},"2028-08-30",{"name":441,"class":43},"Jose Ivan Rodriguez de Molina Serrano",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":17,"sex":18,"minAge":298,"maxAge":4,"enrollmentInfo":450,"targetDuration":452,"studyType":23,"phases":4,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":468},"100596034","immune-responses-to-dengue-and-sepsis-100596034","NCT07040202","Immune Responses to Dengue and Sepsis","Evaluating Immune Responses to Dengue and Sepsis in Hospitalized Patients in Cambodia","DEN-SEP","Inclusion Criteria:\n\n* Patients with dengue-like illness:\n\nPatients presenting with dengue-like symptoms for a duration of maximum 72h before inclusion. Dengue-like symptoms include: presentation with oral temperature \\>38°C AND at least two of the following symptoms suggestive of dengue-like illness: headache, retro-orbital pain, myalgia, joint pain, rash, any bleeding symptoms, nausea or vomiting, lethargy or restlessness , abdominal pain, liver enlargement\n\n* Sepsis patients:\n\nPatients admitted for less than 48 hours with a primary diagnosis of sepsis as per treating team AND have blood cultures ordered AND on empiric antibiotics due to concern for bacterial infection.\n\n* Healthy controls:\n\nParticipants with no chronic illness, no regular medications, no febrile illness in 28 days, no diagnosis of or treatment for dengue or bacterial infection in the past 6 months.\n\nExclusion Criteria:\n\n* For biobanking purposes, children less than 2 years of age, and individuals who are pregnant, pregnant within the last 90 days, and\u002For breastfeeding are excluded due to restrictions on the blood volumes and the repeated sampling times.\n* Individuals that do not provide informed consent will not be included for the study.\n* Severe\u002Fchronic\u002Frecurrent pathological conditions: clinically significant autoimmune disease or immunodeficiency (including history of organ transplant), haematologic disorders, cardiac diseases, diabetes, cancer, HIV, chronic hepatic or renal insufficiency.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within the 6 months prior to the inclusion. For corticosteroids, this will mean a dose equivalent to 20 mg\u002Fday of prednisone or equivalent for \\> 2 weeks (inhaled and topical steroids allowed)\n* Chronic administration of NSAIDs, including aspirin: prolonged intake (\\>2 weeks) within 6 months before study or any intake within the 7 days preceding sampling \\[exception for low dose aspirin: maximum 250mg\u002Fdaily\\]\n* Any underlying, chronic, or current condition that, in the opinion of the investigator, may interfere with their participation in the study.\n* Expected death in the next 48-hours",{"count":451,"type":22},240,"21 Days","The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, sepsis, or healthy people. The investigators will perform multiple analyses on the blood samples and compare results between dengue patients and those with sepsis and healthy people.",[26,455],"Sepsis",[86,457,458,459],"sepsis","observational","infection","2025-06-24",{"date":462,"type":36},"2025-06-27",{"date":464,"type":36},"2025-06-02",{"date":466,"type":22},"2026-12",{"name":386,"class":43},3,{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":18,"minAge":476,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":55,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":44},"100573503","phase-2-efficacy-of-montelukast-in-preventing-transaminase-elevation-in-adult-dengue-patients-100573503","NCT06747130","Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients","Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients: a Randomized, Double-blind, Placebo Controlled, Superiority Trial","Inclusion Criteria:\n\n* Patient age \\>18 years\n* Dengue infection diagnosed by NS1 antigen, or polymerase chain reaction\n* Admitted to the hospital\n* Written informed consent from patient or attending relative able to and willing to give informed consent\n\nExclusion Criteria:\n\n* Other possible cause of fever other than dengue infection\n* Pregnancy\n* Unable to take medication\n* Aminotransferase level above 150 U\u002Fl\n* Allergy to paracetamol or tramadol\n* Paracetamol indicated for condition other than dengue infection\n* Critically ill patient who need ICU or invasive ventilation support\n* History of cirrhosis\n* Unable to communicate\n* Other indication of montelukast\n* History of psychiatric illness","20 Years",{"count":478,"type":22},82,[57,58],"The goal of this clinical trial is to learn if drug montelukast works to treat dengue in adults. It will also learn about the safety of drug montelukast . The main questions it aims to answer are:\n\nDoes drug montelukast lower the incidence of liver enzyme elevations in participants ? What medical problems do participants have when taking drug montelukast ?",[26,482,483],"Montelukast","Transaminases","2025-05-27",{"date":486,"type":36},"2025-05-29",{"date":488,"type":36},"2025-01-31",{"date":490,"type":22},"2027-01",{"name":492,"class":43},"Phramongkutklao College of Medicine and Hospital",{"id":494,"slug":495,"hasResults":11,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":17,"sex":18,"minAge":499,"maxAge":500,"enrollmentInfo":501,"targetDuration":4,"studyType":55,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":4},"100593098","effectiveness-evaluation-of-the-mosquito-free-campus-initiative-on-dengue-fever-prevention-and-control-a-cluster-randomized-controlled-trial-100593098","NCT07002021","Effectiveness Evaluation of the \"Mosquito-Free Campus\" Initiative on Dengue Fever Prevention and Control: A Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* Primary and middle school students within the age range of 6-15 years.\n* The primary and middle schools are located in Yuexiu District, Baiyun District of Guangzhou city or Nanhai District of Foshan City.\n* The schools have the necessary infrastructure, management level and resource allocation to participate in dengue fever prevention and control.\n* The schools agree to implement the intervention measures during the research period.\n* The schools are willing to provide baseline data and participate in subsequent assessments before the intervention is implemented.\n\nExclusion Criteria:\n\n* Unwilling to participate in the project.\n* Participants (students or staff members) are unable to participate in the intervention or withdraw from the study due to personal reasons.","6 Years","15 Years",{"count":502,"type":22},3940,[81],"The goal of this cluster randomized controlled trial is to evaluate the effect of health education interventions on the score of the knowledge, attitudes, and practices (KAP) of dengue in in primary and middle school students in the city of Guangzhou and Foshan in China.\n\nIndividuals aged 6 to 15 years who are in grades 1-9 in primary schools in Guangzhou and Foshan will be enrolled. 20 primary schools will be randomly selected, with half designated as intervention group schools and the remaining half as control group schools. The intervention group will receive a health education intervention focused on dengue prevention every semester for 6 months, while the control group will continue with their routine school health education for 6 months.\n\nResearchers will compare the differences in the score of the KAP of dengue between the intervention and control groups after 6 months to see if health education can improve knowledge, attitudes and practices of dengue among primary and middle school students.",[26,506],"Infection Prevention",[508,509,510],"health education","schools","China","2025-05-25",{"date":513,"type":36},"2025-06-03",{"date":515,"type":22},"2025-06-15",{"date":517,"type":22},"2026-06-01",{"name":519,"class":43},"Sun Yat-sen University",{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":244,"enrollmentInfo":527,"targetDuration":4,"studyType":55,"phases":529,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":4},"100585872","early-phase-1-safety-virological-and-immunological-assessment-of-the-controlled-dengue-human-infection-model-in-dengue-immune-participants-in-thailand-dhit-immune-100585872","NCT06908018","Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)","DHIT-Immune","Inclusion Criteria:\n\n1. Thai healthy volunteers, aged between 18 to 40 years old, weight is greater than or equal to 50 kg and have Thai language literacy.\n2. Have not given blood donation in the past 3 months.\n3. Education: high school diploma or above\n4. Positive dengue-immune status against DENV-1 and\u002For DENV-3 and\u002For DENV-4 with naive DENV-2 status by the standard FRNT 50% (FRNT50) as follows: FRNT50 titer against\n\n   * DENV1 ≥ 1:5 and\u002For\n   * DENV3 ≥ 1:5 and\u002For\n   * DENV4 ≥ 1:5 with\n   * DENV2 ≤ 1:16\n5. Willingness to participate in the study as evidenced by signing the informed consent document.\n6. Female participants of childbearing potential should be agreed to either abstinence or use at least one primary form of contraception from the time of screening for rDEN2Δ30-7169 administration until 1 month after complete course of Dengue vaccination (Study Day 298).\n\nExclusion Criteria:\n\n1. For female participants: Currently pregnant, as determined by positive urine human choriogonadotropin (HCG) test or breast-feeding, and given birth or abortion within 6 months.\n2. History of previous acute undifferentiated febrile illness leading to hospitalization in the past 3 months.\n3. Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the subject's ability to understand and cooperate with the requirements of the study protocol.\n4. Any significant alcohol or drug abuse in the past 12 months that has caused medical, occupational, or family problems, as indicated by subject history.\n5. History of a severe allergic reaction or anaphylaxis.\n6. Severe asthma (emergency room visit or hospitalization within the last 6 months).\n7. Any known immunodeficiency syndrome.\n8. Having any pre-existing medical conditions consist of thrombocytopenia, autoimmune disease and cancer based on history, physical examination, and\u002For laboratory studies.\n9. Current use of anticoagulant medications (this includes anti-platelet medication such as aspirin or non-steroidal anti-inflammatory medications).\n10. Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 28 days prior to or following vaccination. An immunosuppressive dose of corticosteroids is defined as ≥ 10 mg of a prednisone equivalent per day for ≥ 14 days.\n11. Asplenia\n12. Receipt of any vaccine within 28 days or a killed vaccine within 14 days prior to receiving virus administration, or anticipated receipt of any vaccine during the 28 days following rDEN2Δ30-7169 administration.\n13. Has an obvious history of receiving any type of dengue vaccine or has previously participated in dengue vaccine research.\n14. Receipt of blood products within the past 6 months, including transfusions or immunoglobulin, or anticipated receipt of any blood products or immunoglobulin during the 28 days following rDEN2Δ30-7169 administration.\n15. History of allergy to Qdenga vaccine or any components of the vaccine.\n16. Previous episode of severe dengue infection defined by WHO 2009\n17. Screening laboratory values of Grade 1 or above (as defined in this protocol) for ANC (\\\u003C750 \u002Fmm3), Platelet (\\\u003C100,000 \u002Fmm3), PT (\\> 1.25 x ULN), APTT (\\> 1.66 x ULN), ALT (\\>2.5 x ULN) and plasma creatinine (\\> 1.3 x ULN OR Increase to \\>1.3 x participant's baseline).\n18. A participant with hemoglobin level less than 10 g\u002FdL at initial screening.\n19. Body temperature is greater than or equal to 38.0 °C (Oral)\n20. HIV infection, as indicated by anti-HIV screening assays.\n21. Hepatitis C virus (HCV) infection, as indicated by anti-HCV screening assays.\n22. Hepatitis B virus (HBV) infection, as indicated by hepatitis B surface antigen (HBsAg) and\u002For anti-HBc screening.\n23. Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, or would render the subject unable to comply with the protocol.",{"count":528,"type":22},12,[530],"EARLY_PHASE1","rDEN2Δ30-7169 is a dengue challenge strain that previously reports its viremia induction effect in participants with minimal symptoms in US flavivirus naïve participants. Moreover, preliminary result of five Thai dengue naïve participants from previous project (registered number NCT05476757) demonstrated 100% viremia status without severe adverse event after 60 days post-virus challenge. However, result from previous project may not fully represent the clinical manifestation and immunological responses of major population of endemic areas, where most people in endemic area have dengue immune status. Therefore, this controlled human infection model protocol proposes to challenge the attenuated virus in 12 dengue-immune participants recruited from Bangkok metropolitan area, Thailand. We aim to assess the safety, viremia, NS1 antigenemia profile, and immunogenicity of the challenge virus in the dengue immune participants. After finish safety assessment, all participants will be vaccinated with a full course of dengue vaccines to prevent recurrent dengue infection. Immunological responses after vaccination will be also evaluated the vaccine efficacy.\n\nOur expected outcomes are all participants present viremia profiles after virus challenge without serious adverse events (SAE). The exploratory profiles include assesment of immune profiles and parameters comparison with the other dengue challenge study.",[533,26,534,535],"Safety Issues","Viremia","Immune-related Adverse Event","2025-04-01",{"date":538,"type":36},"2025-04-03",{"date":540,"type":22},"2025-09",{"date":542,"type":22},"2028-09",{"name":544,"class":43},"Mahidol University",{"id":546,"slug":547,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":55,"phases":553,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":44},"100584864","impact-of-iit-sit-on-dengue-clusters-100584864","NCT06894901","Impact of IIT-SIT on Dengue Clusters","Assessing the Efficacy of Incompatible Insect Technique Coupled with Sterile Insect Technique (IIT-SIT) to Manage Large Dengue Clusters: a Randomized Controlled Trial","Eligible dengue clusters will be limited to public housing estates and with at least 10 dengue cases comprising that dengue cluster before allocation into intervention or control arms. The selected clusters will be in areas with relatively high sector-level GAI of at least 0.2 at the time of the 10th reported case. Additionally, the first 10 cases must be reported within 30 days of the first case. Additionally, clusters must be in areas which have never experienced Wolbachia-Aedes releases and at least 700 m away from existing Wolbachia-Aedes release areas.",{"count":218,"type":22},[81],"This randomized controlled trial aims to evaluate the efficacy of Wolbachia-infected male mosquitoes combined with sterile insect technique (IIT-SIT) to mitigate active dengue transmission in Singapore.",[26],"2025-03-19",{"date":558,"type":36},"2025-03-25",{"date":560,"type":22},"2025-03-20",{"date":562,"type":22},"2028-01-20",{"name":564,"class":234},"National Environment Agency, Singapore",{"id":566,"slug":567,"hasResults":11,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":11,"sex":18,"minAge":573,"maxAge":574,"enrollmentInfo":575,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":577,"conditions":578,"keywords":581,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":44},"100426957","dengue-vaccine-strategy-in-children-aged-9-to-17-years-in-the-french-caribbean-100426957","NCT04839757","Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean","Preparing for the Use of a Dengue Vaccine in the French Caribbean Islands of Martinique and Guadeloupe : the DengueSEA Study","DengueSEA","CHILDREN\n\nInclusion Criteria for children:\n\n* Any child aged 9 to 17 years presenting to one of the hospital departments participating in the study at the University Hospitals of Martinique or Guadeloupe\n* Need to take a blood sample or place a peripheral venous line for the management of the child\n* Residence in Martinique or Guadeloupe since at least one year\n* Information on the study given to the child and his\u002Fher parent or legal guardian\n* Collection of the parent's or legal guardian's non-objection to the child's participation\n\nExclusion Criteria for children:\n\n* Presence of fever or suspected acute infection\n* Presence of an immune deficiency or any other dysimmune condition\n\nPARENTS\n\nParental inclusion criteria (\"vaccine acceptability\" survey)\n\n* Collection of the parent's or legal guardian's non-objection to participate in the Dengvaxia® vaccine acceptability survey\n* Comprehension of spoken and written French\n\nNon-inclusion criteria for parents (vaccine acceptability survey)\n\n\\- None of the above","9 Years","17 Years",{"count":576,"type":22},590,"Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits. The 2018 European marketing authorization of the tetravalent chimeric yellow fever \u002F dengue vaccine (Dengvaxia®) is a major step forward in the fight against the disease. Dengvaxia® is indicated for the prevention of dengue due to serotypes DENV 1-4 in subjects aged 9 to 45 years with a history of infection with the dengue virus and living in endemic areas (seroprevalence of at least 70% in the target population).\n\nDengue seroprevalence data in the French Caribbean territories of Martinique and Guadeloupe dates back to 2011 and concerns only adult blood donors aged 18 to 70 years. To date, no data exists for individuals aged 9 to 17 years in the region.\n\nIn order to implement an optimal vaccine introduction strategy for these territories, the main aim of the DengueSEA study is to estimate the seroprevalence of the Dengue viruses (DENV 1-4) in 9-17 year olds giving a blood sample as part of care in hospital departments of the French Caribbean islands of Martinique and Guadeloupe.",[26,579,367,580],"Vaccination","Infectious Disease",[86,582,583,584,585,586],"seroprevalence","children","adolescents","vaccination strategy","French Carribean","2025-02-20",{"date":589,"type":36},"2025-02-21",{"date":591,"type":36},"2021-06-03",{"date":593,"type":22},"2026-02",{"name":595,"class":43},"University Hospital Center of Martinique",{"id":597,"slug":598,"hasResults":11,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":4},"100504795","study-of-dengue-in-patients-with-autoimmune-diseases-during-the-epidemics-of-2020-and-2021-in-reunion-island-100504795","NCT05852977","Study of Dengue in Patients With Autoimmune Diseases During the Epidemics of 2020 and 2021 in Reunion Island","Study of Dengue in Patients With Autoimmune Diseases With or Without Immunosuppressive Treatment During the Epidemics of 2020 and 2021 in Reunion Island","MAIDEN","Inclusion Criteria:\n\n* Age ≥18 years\n* Patient with autoimmune or autoinflammatory disease\n* Confirmed diagnosis of dengue (in 2020 or 2021): serological test, antigenic test or PCR test to confirm the diagnosis according to current criteria\n\nExclusion Criteria:\n\n* minor\n* opposition to the re-use of data\n* patient not followed in Reunion\n* protected adult (guardianship or curatorship) or under legal protection",{"count":605,"type":22},90,"It is not known whether there is a different clinical profile of dengue in patients with immune system dysfunction. Preliminary data and previous literature suggest that autoimmune diseases, and in particular their treatment, may favour the evolution to severe forms of dengue.\n\nOur research hypothesis is that the clinico-biological presentation of dengue might be different in case of autoimmune disease, either on the side of overactivation (autoimmune and auto inflammatory diseases without treatment) or immunodepression (autoimmune and auto inflammatory diseases under immunosuppressive treatment).",[26],"2023-05-02",{"date":610,"type":36},"2023-05-10",{"date":612,"type":22},"2023-06",{"date":614,"type":22},"2026-06",{"name":616,"class":43},"Centre Hospitalier Universitaire de la Réunion"]